Dengue Fever Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Key Companies - Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dengue Fever pipeline constitutes 10+ key companies continuously working towards developing 10+ Dengue Fever treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Dengue Fever Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dengue Fever Market.

The Dengue Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dengue Fever Pipeline Report: https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dengue Fever treatment therapies with a considerable amount of success over the years.
• Dengue Fever companies working in the treatment market are Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others, are developing therapies for the Dengue Fever treatment
• Emerging Dengue Fever therapies such as - anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others are expected to have a significant impact on the Dengue Fever market in the coming years.
• In December 2021, Janssen Research & Development initiated a Phase II a, Randomized, Double blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ64281802 in Participants With Confirmed Dengue Fever
• In December 2020, KAUST announced a collaboration with Janssen Pharmaceutical Companies of Johnson &Johnson to explore opportunities for research and innovation in the area of neglected tropical diseases, with a focus on dengue fever. The partnership signifies Johnson & Johnson's first university partnership in the Kingdom of Saudi Arabia.

Dengue Fever Overview
Dengue fever is a disease caused by four dengue viruses spread by the Aedes aegypti mosquito. The Center for Disease Control and Prevention (CDC) estimates that at least 400 million cases of dengue fever occur across the globe every year.

Get a Free Sample PDF Report to know more about Dengue Fever Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Dengue Fever Drugs Under Different Phases of Clinical Development Include:
• Research programme: anti-RNA virus therapeutics - Kino Pharma
• ABX220: Abivax
• TAK003: Takeda
• V180: Merck Sharp & Dohme
• AV1: AbViro LLC
• Infectious diseases therapeutics Programme: Plex Pharmaceuticals
• CDX DENV: Codagenix
• AT-752: Atea Pharmaceuticals
• LD vehicle-GNP: Emergex Vaccines
• VIS513: Visterra
• JNJ-64281802: Janssen Research & Development
• TV003: Merck & Co.
• V 503: Takeda

Route of Administration
Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Molecule Type
Products have been categorized under various Molecule types, such as
• Small molecules
• Proteins
• Monoclonal antibodies
• Product Type

Dengue Fever Pipeline Therapeutics Assessment
• Dengue Fever Assessment by Product Type
• Dengue Fever By Stage and Product Type
• Dengue Fever Assessment by Route of Administration
• Dengue Fever By Stage and Route of Administration
• Dengue Fever Assessment by Molecule Type
• Dengue Fever by Stage and Molecule Type

DelveInsight's Dengue Fever Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Dengue Fever product details are provided in the report. Download the Dengue Fever pipeline report to learn more about the emerging Dengue Fever therapies at:
https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Dengue Fever Therapeutics Market include:
Key companies developing therapies for Dengue Fever are - Takeda Pharmaceutical Co Ltd, BioNet-Asia Co Ltd, Emergex Vaccines Holding Ltd, Johnson & Johnson, 60 Degrees Pharmaceuticals LLC, and Abivax SA among others.

Dengue Fever Pipeline Analysis:
The Dengue Fever pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dengue Fever with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Fever Treatment.
• Dengue Fever key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dengue Fever Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue Fever market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dengue Fever drugs and therapies-
https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dengue Fever Pipeline Market Drivers
• Fastest spreading mosquito-borne viral disease, search of novel tools and innovative strategies to interrupt transmission of dengue, integration of vector management approaches is encouraged are some of the important factors that are fueling the Dengue Fever Market.

Dengue Fever Pipeline Market Barriers
• However, challenging research due to multiple stereotypes, disease risks may change and shift with climate change in tropical and subtropical areas and other factors are creating obstacles in the Dengue Fever Market growth.

Scope of Dengue Fever Pipeline Drug Insight
• Coverage: Global
• Key Dengue Fever Companies: Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others
• Key Dengue Fever Therapies: anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others
• Dengue Fever Therapeutic Assessment: Dengue Fever current marketed and Dengue Fever emerging therapies
• Dengue Fever Market Dynamics: Dengue Fever market drivers and Dengue Fever market barriers

Request for Sample PDF Report for Dengue Fever Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Dengue Fever Report Introduction
2 Dengue Fever Executive Summary
3 Dengue Fever Overview
4 Dengue Fever- Analytical Perspective In-depth Commercial Assessment
5 Dengue Fever Pipeline Therapeutics
6 Dengue Fever Late Stage Products (Phase II/III)
7 Dengue Fever Mid Stage Products (Phase II)
8 Dengue Fever Early Stage Products (Phase I)
9 Dengue Fever Preclinical Stage Products
10 Dengue Fever Therapeutics Assessment
11 Dengue Fever Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Dengue Fever Key Companies
14 Dengue Fever Key Products
15 Dengue Fever Unmet Needs
16 Dengue Fever Market Drivers and Barriers
17 Dengue Fever Future Perspectives and Conclusion
18 Dengue Fever Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Dengue Fever Market https://www.delveinsight.com/report-store/dengue-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dengue Fever-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.